A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.
Maffioli M, Mora B, Ball S, Iurlo A, Elli EM, Finazzi MC, Polverelli N, Rumi E, Caramella M, Carraro MC, D'Adda M, Molteni A, Sissa C, Lunghi F, Vismara A, Ubezio M, Guidetti A, Caberlon S, Anghilieri M, Komrokji R, Cattaneo D, Della Porta MG, Giorgino T, Bertù L, Brociner M, Kuykendall A, Passamonti F.
Maffioli M, et al. Among authors: finazzi mc.
Blood Adv. 2022 Mar 22;6(6):1855-1864. doi: 10.1182/bloodadvances.2021006889.
Blood Adv. 2022.
PMID: 35130339
Free PMC article.